Summary of Significant Accounting Policies - Schedule of Percentage of Revenues and Accounts Receivables from Customers (Details) - Customer	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
VA MVP | Revenue
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage	54.00%	45.00%	56.00%	46.00%
VA MVP | Accounts Receivable
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage			30.00%
Merck & Co., Inc. | Revenue
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage		16.00%		14.00%
Merck & Co., Inc. | Accounts Receivable
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage					10.00%
Pfizer Inc. | Revenue
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage	23.00%		20.00%
Pfizer Inc. | Accounts Receivable
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage			38.00%		33.00%
Customer D | Revenue
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage	12.00%
Customer D | Accounts Receivable
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage			18.00%
Customer E | Revenue
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage		10.00%
Customer F | Accounts Receivable
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage					17.00%
Customer G | Accounts Receivable
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage					10.00%